证券代码：301060 证券简称：兰卫医学 公告编号：2025-001 上海兰卫医学检验所股份有限公司 尊敬的投资者，感谢您的提问！ 投资者关系活动记录表 投资者关系活动 类别 □特定对象调研 □分析师会议 □媒体采访 业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他（请文字说明其他活动内容） 参与单位名称及 人员姓名 投资者网上提问 时间 2025 年 5 月 15 日（周四）下午 15:00-16:30 地点 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net）采用网 络远程的方式召开业绩说明会 上市公司接待人 员姓名 1、董事长、总经理：曾伟雄先生； 2、董事、副总经理：毛志森先生； 3、副总经理：方国伟先生； 4、董事会秘书：高文俊先生； 5、财务中心负责人：王海洋女士； 6、独立董事：石道金先生； 7、保荐代表人：唐蕾女士。 投资者关系活动 主要内容介绍 投资者提出的问题及公司回复情况 公司就投资者在本次说明会中提出的问题进行了回复： 1、高管您好，请问您如何看待行业未来的发展前景？谢谢。 尊敬的投资者，感谢您的提问！ 我们认为，第三方医学诊断服务仍属于快速发展的行业 ...

| 上海润达医疗科技股份有限公司 | | --- | | 会 | | 议 | | 材 | | 料 | | 【二零二五年五月】 | | 上海润达医疗科技股份有限公司 | | 一、2024年年度股东大会议程--------------------------------------------1 | | 二、会议注意事项----------------------------------------------------------------------3 | | 三、审议事项 | | 关于 2024 年度利润分配方案的议案--------------------------50 | | 请授信额度的议案-------------------------------------------------------------------51 | | 关于公司 2025 年度担保预计的议案--------------------------52 | | 案------------------------------------------------------------------------------- ...

消息面上，据一财，日前美国财政部部长表示，不希望与中国全面脱钩，但是要把医药等产业带回美国。针对美国官员的上述表态，中国医药产业从业人士 认为，美国原料药的供应大量来自于中国；在创新药开发方面，中国企业发挥的作用越来越大，如果强行脱钩，部分美国药企成本预计增加一半。 此外，5月15日，创新药龙头企业恒瑞医药正式启动H股全球公开发售，计划发行2.25亿股H股（假设超额配售权及发售量调整权未行使），其中香港公开发 售占5.5%，国际配售94.5%，发行价区间定为每股41.45—44.05港元。若全额行使超额配售权及发售量调整权，发行H股最高达2.97亿股，最高募资额可达 130.8亿港元。这意味着此次恒瑞医药募资额将成为近五年港股医药企业IPO最高募资额。 | 证券代码 | 证券简称 | 今日涨幅 | 年内涨幅 | 基金管理人 | | --- | --- | --- | --- | --- | | 512120.SH | 医药50ETF | 0.96% | 2.93% | 华安县金 | | 516820.SH | 医疗创新ETF | 0.88% | 2.69% | 平安基金 | | 517110.SH | 创新药 ...

Group 1 - The Shanghai Composite Index has surpassed 3400 points, driven by strong performance in the securities and insurance sectors, marking one of the best-performing sectors in recent years [1][5] - A report from Goldman Sachs highlights that banks, which have the highest underweight ratio among public funds, are showing the strongest performance, while electronics, with the highest overweight ratio, are performing the weakest [2][4] - New regulations for public funds state that if fund performance lags behind benchmarks by more than 10%, fund managers' compensation will be significantly affected, prompting a shift in holdings towards benchmarks [4] Group 2 - Despite a decline in net profits for major banks in Q1, the banking sector has quickly rebounded to new highs, also boosting the securities and insurance sectors [5] - There is skepticism regarding whether fund managers will generally increase allocations to the financial sector, as the narrative of aligning with benchmarks may not hold true in all cases [6] - The Chinese government has recently announced a tariff adjustment on the U.S., effective from May 14, which may impact market dynamics [8] Group 3 - The U.S. CPI data shows a year-on-year increase of 2.3% in April, the lowest level since February 2021, which may influence Federal Reserve policy decisions [10] - A historic commercial agreement between the U.S. and Saudi Arabia involves a $600 billion investment commitment from Saudi Arabia, which is expected to boost U.S. markets [12] - The A-share AI medical sector is anticipated to enter a new growth phase, driven by recent market trends and favorable conditions [12] Group 4 - The market closed with the Shanghai Composite Index up 0.86%, and the ChiNext Index up 1.01%, indicating overall positive market sentiment [13] - Non-bank financials, transportation, food and beverage, and retail sectors led the market gains, while defense, beauty care, and machinery sectors lagged [15]

Group 1 - The Hang Seng Medical Index ETF has shown significant liquidity with an intraday turnover of 2.58% and a transaction volume of 6.738 million yuan, with an average daily transaction volume of 28.499 million yuan over the past month [2] - The ETF has experienced a notable increase in scale, growing by 4.1161 million yuan over the past week, ranking first among comparable funds, and its shares increased by 6 million units, also ranking first [2] - In terms of capital inflow, the ETF has seen net inflows on 4 out of the last 5 trading days, totaling 13.3303 million yuan [2] Group 2 - The current price-to-earnings ratio (PE-TTM) of the Hang Seng Medical Healthcare Index is 23.43, which is in the 4th percentile over the past year, indicating that the valuation is lower than 96% of the time in the past year and is at a historical low [2] - The top ten weighted stocks in the Hang Seng Medical Healthcare Index include WuXi Biologics, BeiGene, Innovent Biologics, and others, collectively accounting for 56.46% of the index [2] Group 3 - Industry experts believe that after four years of decline, the market's pessimistic expectations for the healthcare sector have been fully digested, and advancements in emerging technologies such as innovative drugs and AI healthcare are ongoing, leading to a potential recovery in the pharmaceutical sector [3] - The recovery in the healthcare sector is expected to be sustainable over a longer period, with a focus on increasing allocations towards emerging areas like AI healthcare and brain-computer interfaces [3] - Investors without stock accounts can access investment opportunities in the Hong Kong healthcare sector through the Hang Seng Medical Index ETF linked fund (018433) [3]

A股今日冲高回落，深证成指、创业板指翻绿；港股大幅跳水，恒生指数跌近2%，恒生科技指数跌超3%。 航运概念尾盘拉升，银行板块再度走强。 具体来看，三大股指早盘全线高开，随后震荡回落，深证成指、创业板指翻绿。截至收盘，沪指微涨0.17%报3374.87点，深证成指跌0.13%报10288.08点，创业板指 跌0.12%报2062.26点，上证50指数涨0.2%，沪深北三市合计成交13262亿元，成交额较昨日小幅萎缩。 场内超3200股飘绿，军工板块回调，华伍股份、莱赛激光、通易航天等跌超10%，奥普光电跌停；航运概念尾盘拉升，宁波海运、宁波远洋、南京港等涨停；光伏 产业链股崛起，东方日升涨约17%，协鑫集成、宝馨科技等涨停；银行板块再度走强，上海银行、浦发银行、成都银行、江苏银行等盘中均创出新高；AI医疗概念 上扬，华大基因涨超14%，贝瑞基因涨停。 港股方面，舜宇光学科技、比亚迪电子跌超7%，蔚来、小鹏汽车跌超5%，中芯国际、华虹半导体跌逾4%，优必选逆市涨近6%。 多只银行股创新高 银行板块今日再度走强，截至收盘，重庆银行涨超4%，上海银行、厦门银行、浦发银行等涨超3%，成都银行、江苏银行涨约2%。值得注意 ...

5月13日，港股全天表现低迷，三大指数呈现低开低走行情，尤其是恒生科技指数大跌3.26%，恒生指数、国企指数分别下跌1.87%及2.02%，恒指更是止步8 连涨。 昨日中美关税削减重大利好，未能持续推动市场上行。 | 名称 | | 最新价 | 涨跌额 | 涨跌幅 √ | | --- | --- | --- | --- | --- | | 恒生指数 800000 | min | 23108.27 | -441.19 | -1.87% | | 国企指数 800100 | min | 8386.21 | -173.02 | -2.02% | | 恒生科技指数 800700 | min | 5269.66 | -177.69 | -3.26% | 盘面上，作为市场风向标的大型科技股集体走低，昨日受关税影响而大涨的苹果概念股、汽车股、半导体芯片股跌幅较为明显；中资券商股、军工股、手游 股、体育用品股、保险股、电信股、家电股纷纷走低。另一方面，机构对黄金长期展望乐观，黄金股再度活跃，生物医药股集体反弹，海运股、内银股多数 上涨。 具体来看： 科技股低迷，美团、快手跌超4%，阿里、小米跌超3%，腾讯、京东、百度纷纷跟跌。消 ...

5月份，增量政策可能不多，但储备政策不少，政策定力仍然很强，目标是应对关税的冲击。因此，市 场在度过业绩风险后仍然会关注科技成长主题。内需相关板块仍会是国内政策的首要着力点，低利率环 境下业绩稳定的高股息板块仍有配置价值。除此以外，在可能出现的关税缓和过程中，那些品牌力强、 定价能力强、替代难度大的公司有望迎来估值的修复。 谭小兵：看好有边际变化的成长股 4月份市场呈现V字形走势，内需与红利好于成长股。展望5月份，进入业绩真空期，市场对指数填补之 后能否继续上攻还是存在分歧，个人相对还是偏乐观：一方面是国内政策会逐步兑现；另一方面中美谈 判或拉开序幕，这有利于修复市场的风险偏好。方向上看好有边际变化的成长股。 回顾4月，美国"对等关税"来袭，全球市场剧烈波动，就中国资产来看，月内A股和港股主要指数收 跌。进入5月，尽管外部不确定性因素依然存在，但中美关税谈判窗口有望来临，国内一揽子增量政策 也在加速落地，为国内股市稳定发展带来有力支撑。 展望后市，市场将会如何演绎？哪些投资机会值得关注？一起来看看长城基金权益基金经理们的观点吧 ~ 杨建华：持续关注关税政策 展望5月，关税政策及中美贸易谈判仍将会成为左右市场的 ...

Group 1 - The core viewpoint is that the pharmaceutical sector is focusing on innovation, with a positive trend in innovative drugs supported by policies and increasing global competitiveness [2] - The Shanghai Stock Exchange Science and Technology Innovation Board Biomedicine Index has shown a 1.27% increase, indicating a recovery in the biotech sector [1] - The ETF tracking the Biomedicine Index has seen a 1.17% rise, with significant trading volume exceeding 8.12 million yuan, reflecting investor interest [1] Group 2 - The pharmaceutical industry is expected to see a recovery in demand by 2025, particularly in the consumer healthcare sector, driven by improving economic fundamentals [2] - The medical device sector is also anticipated to improve by 2025, indicating a broader recovery in the healthcare industry [2] - AI in healthcare is highlighted as a significant technological trend that could bring changes to the pharmaceutical industry [2] Group 3 - The pharmaceutical index has stabilized after a period of decline since 2021, with signs of recovery beginning in Q4 2024 [2] - The ongoing innovation in the pharmaceutical sector, along with favorable drug procurement policies, is expected to drive a new growth cycle [2] - The aging population and unmet clinical needs are contributing to long-term growth trends in the pharmaceutical industry [2]

政策动向 默沙东新型抗菌药物锐可博®在华上市 5月12日，默沙东宣布，其新型碳青霉烯/酶抑制剂复合制剂锐可博®（注射用亚胺西瑞）已正式在中国 境内上市，适用于治疗18岁及以上患者由敏感革兰阴性菌引起的下列感染：医院获得性细菌性肺炎和呼 吸机相关性细菌性肺炎（HABP/VABP）；治疗药物选择有限或无替代治疗的复杂性尿路感染（cUTI） （包括肾盂肾炎）；治疗药物选择有限或无替代治疗的复杂性腹腔内感染（cIAI）。首批药物已在默沙 东中国杭州工厂完成包装，实现本土首发。 资本市场 晶泰控股拟2.5亿元收购上海四维医学科技90%股权 5月11日，晶泰控股宣布以总计2.5亿元对价收购国内最大规模的远程心电图(ECG)诊断服务解决方案企 业——上海四维医学科技有限公司(四维医学)90%的股权，上海交通大学拥有剩余10%股权。收购后， 四维医学作为晶泰控股的子公司，将支撑晶泰科技在 AI医疗领域的重要业务板块，并赋能其新药研发 业务。 怡和嘉业与翰宇药业、翰宇健康签署合作协议 黑龙江八部门联合治理"神医"广告乱象 为贯彻落实国家市场监管总局《关于维护广告市场秩序营造良好消费环境的通知》和重点领域广告监管 工作部署会要求 ...